Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02530944 · ClinicalTrials.gov registry record
Web-based Genetic Research on Lupus
A clinical trial of Systemic Lupus Erythematosus, sponsored by 23andMe.
- Completed
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT02530944: Completed study of Systemic Lupus Erythematosus, sponsored by 23andMe.
NCT02530944 is a study of Systemic Lupus Erythematosus that has completed, run by 23andMe. The registered enrollment target is 5,000 participants, above the 330-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (1415% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02530944, a study of Systemic Lupus Erythematosus, has completed, sponsored by 23andMe.
- COMPLETED
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this new lupus research study is two-fold: first, to understand the genetic associations found between people's DNA and this disease, and second, to apply this understanding to drug development efforts with the investigator's partners at Pfizer.
Conditions Studied
Study Locations (1)
California
- Www.23Andme.Com/Lupus - Mountain View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-10-31 |
What the finished NCT02530944 record still lists
NCT02530944 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 330-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (1415% higher).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 0 interventions.
NCT02530944 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02530944 about?
NCT02530944 is a clinical study titled "Web-based Genetic Research on Lupus". The goal of this new lupus research study is two-fold: first, to understand the genetic associations found between people's DNA and this disease, and second, to apply this understanding to drug development efforts with the investigator's partners at Pfizer.
What is the current status of trial NCT02530944?
This trial is currently completed. The enrollment target is 5,000 participants. The study started on 2015-05. Estimated completion is 2017-10-31.
What conditions does trial NCT02530944 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
Who is sponsoring clinical trial NCT02530944?
This trial is sponsored by 23andMe, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02530944 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02530944's enrollment target sits among peer trials
5,000 1st of 99 the highest of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RECRUITING
-
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia